ClinicalTrials.gg
Active, not recruitingNCT04295811ESOGUARDBE2Updated Sep 21, 2026

Efficacy of EsoGuard Assay on Esophageal Surface Cells Collected With EsoCheck vs EGD for the Diagnosis of BE or EAC

An interventional study of EsoGuard (lab assay) and Esophagogastroduodenoscopy in Barrett Esophagus, Esophageal Adenocarcinoma and Barretts Esophagus With Dysplasia, sponsored by Lucid Diagnostics, Inc.. Active, not recruiting at 35 sites in 2 countries. Open to male participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-21.

Sponsored by Lucid Diagnostics, Inc. · Not applicable, Interventional, and Diagnostic

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
784
Allocation
Not applicable
Ages
50 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 209 studies in Barrett Esophagus with a site in United States — 38 open to participants now, 48 under way, none of them phase 3. Barrett Esophagus · United States.

Enrollment
7th of 122
784 · median 58
Started
2020
with 8 others
No phase
78 of 209
13 open now
Primary completion
2027-06
later than 14 of 47 live
Registered
167th of 209
by date
Lead sponsor
5 of 209
Lucid Diagnostics, Inc.

Among the 209 studies in Barrett Esophagus with a site in United States, this one is the 7th largest by enrollment of the 122 interventional ones that give a count, is one of 9 that started in 2020, is one of 78 with no phase, reaches primary completion later than 14 of the 47 other live ones, and was the 167th registered.

Barrett Esophagus

312 studies on the registry are indexed under Barrett Esophagus; 60 are open to participants now.

Browse Barrett Esophagus studies →

Open to participants now

38 of the 209 studies in Barrett Esophagus with a site in United States are open now. Recruiting first, the newest first:

33 more — sign in →

All 38 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 44 Barrett Esophagus studies recruiting now, 31 (70%) set no upper age limit and 2 (5%) stop at 75 or younger; 4 take children under 18; 10 take healthy volunteers.

This study: 50 Years and older · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 209 studies in Barrett Esophagus with a site in United States, or all of them as a file.
02

Study summary

The study will assess the performance of the combined system, i.e., the use of the EsoGuard assay (lab developed test) on cells collected using the EsoCheck (501k cleared device) to detect Barrett's Esophagus (BE), with or without dysplasia, and esophageal adenocarcinoma (EAC) as compared to Esophagogastroduodenoscopy (EGD) plus biopsies in both confirmed cases of BE/EAC and in controls (subjects without a prior diagnosis but undergoing screening for BE/EAC)

Read the detailed description

This is a two phase multicenter study to assess the operating characteristics of the EsoGuard diagnostic assay panel performed on esophageal mucosal cells collected using the EsoCheck cell collection device in known "Cases" of disease (i.e., patients with a history of Barrett's Esophagus (BE) with and without varying degrees of dysplasia or intramucosal adenocarcinoma [IMC]) and in patients with no known history of these conditions. The latter are presumed to be "Controls", though this final determination is made as part of study conduct, not at the time of enrollment.

The study is divided into a Run-In phase and an Efficacy phase. The assignment of a patient to one or the other of these two phases will be made based on two pieces of information: 1) the Final Study Diagnosis (as defined below) and 2) the current tally versus the pre-determined target number of patients already assigned to each of the subgroups (e.g., non-dysplastic Barrett's Esophagus (NDBE), high grade dysplasia {HGD]) for each phase. Patients will first be enrolled into the Run-In phase subgroups. Only once the targeted enrollment for a given Run-In phase subgroup has been reached, subsequent patients with a particular diagnosis will be assigned to the appropriate Efficacy Phase subgroup, until the targeted total number is reached. Run In phase data will be maintained in a separate database from Efficacy phase data. Study conduct is identical in both phases; however, data from each phase will be segregated and analysis of each phase will be used solely for its predetermined purpose without any co-mingling of data. Once assigned, no patient, or their data, will be re-assigned or moved from being a Run-In phase patient to being an Efficacy phase patient, or from the Run-In phase database to the Efficacy phase database, or vice versa.

The Run-In phase will enroll the initial 60 short segment NDBE (also known as short segment Barrett's Esophagus [SSBE]) and 25 long segment NDBE (also known as long segment Barrett's Esophagus [LSBE]) Cases, the initial 10 low grade dysplasia [LGD] Cases, the initial 3 high grade dysplasia [HGD] Cases, and the initial 2 intramucosal adenocarcinoma [IMC] Cases, as well as the initial 100 Controls. The Efficacy phase will enroll 54 Cases each with a Final Study Diagnosis of NDBE, LGD, HGD, and IMC, and 54 Controls.

Run-In phase data will be used solely to derive the optimal numerical cutoffs by which to score mVIM and mCCNA1 (which are two genes where the methylated DNA changes are located) positivity or negativity. These cutoffs serve as the key inputs into an algorithm by which an overall EsoGuard result of positive versus negative is determined. The setting of these cutoffs will be done by Sponsor personnel with full access to all Run-In phase data; the goal will be to optimize overall EsoGuard assay sensitivity and specificity for its intended use as a screening test in the at-risk population. The assay, once validated and locked, will be used to analyze patients' distal esophageal cells obtained in both the Efficacy phase of this Case Control study as well as in a separate Screening study (PR-1039/EG-CL-101) to be conducted in parallel. Only Run-In phase data will be used to set cutoffs. The mVIM and mCCNA1 (i.e., genes with methylated DNA changes) cutoffs will be set and then the EsoGuard assay re validated and "locked", all before any Efficacy phase distal esophageal cells specimens collected from study patients will undergo EsoGuard analysis.

Sponsor personnel will have open access to all Run-In phase data during the enrollment of the Run-In phase in order to determine if the data from patients enrolled to date is sufficient to inform adequately the setting of cutoffs. If Sponsor so determines, it may elect to terminate enrollment in the Run-In phase early (i.e., prior to enrolling the 100 Cases and 100 Controls listed above). If early termination of the Run-In phase is elected, all patients enrolled subsequent to the date Sponsor makes this election will be entered into the Efficacy phase and such subsequent patients will count towards the Efficacy phase enrollment objectives.

As well, should Sponsor complete the intended Run-In phase enrollment of 100 Cases and 100 Controls but determine, upon its assessment of the resulting data, that data from additional Cases could improve the setting of cutoffs, Sponsor may decide to enroll up to 100 additional Run-In phase Cases. These 100 Cases may be in whatever distribution of disease Sponsor elects (i.e., ranging from NDBE through to IMC). In order to augment the Run-In phase patient counts, the Sponsor will set updated targets for enrollment of each Run-In phase subgroup and will assign patients to each Run-In subgroup to be augmented, based on patients' Final Study Diagnosis and on whether the updated subgroup target has been met. When each updated subgroup enrollment target has once again been met, subsequent patients with that subgroup diagnosis will be enrolled into the Efficacy phase.

03

Conditions studied

  • Barrett Esophagus
  • Esophageal Adenocarcinoma
  • Barretts Esophagus With Dysplasia
  • Barrett's Esophagus Without Dysplasia
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

All Patients:

  1. Men aged 50 years and above
  2. ≥5 years either of

    • Gastroesophageal Reflux Disease (GERD) symptoms,
    • GERD treated with proton pump inhibitor (PPI) therapy (whether symptom control is achieved or not), or
    • any combination of treated and untreated periods, as long the cumulative total is at least 5 years
  3. No solid foods eaten for at least 2 hours prior to EsoCheck procedure
  4. One or more of the following:

    • Caucasian race
    • Current or past history of cigarette smoking
    • (BMI) of at least 30 kg/m2
    • First-degree relative with Barrett's Esophagus (BE) or Esophageal Adenocarcinoma (EAC)

Cases:

  1. Previous diagnosis of non-dysplastic Barrett's Esophagus (NDBE), low grade dysplasia (LGD), high grade dysplasia (HGD), and/or intramucosal adenocarcinoma (IMC)
  2. Diagnosis by esophagogastroduodenoscopy (EGD) (with exception of NDBE) was within 4 months prior to study enrollment
  3. Indicated for surveillance EGD or for therapeutic EGD
  4. Able to provide, by day of study EGD, the original glass slide(s) of specimens from most recent prior EGD

Exclusion criteria

Exclusion Criteria:

  1. Inability to provide written
  2. On anti-coagulant drug(s) that cannot be temporarily discontinued
  3. Known history of esophageal varices or esophageal stricture
  4. Any , as deemed in Investigator's medical judgment, to undergoing the EsoCheck procedure, undergoing the EGD procedure, and/or having taken, including but not limited to due to comorbidities such as coagulopathy or a known history of esophageal diverticula, esophageal fistula, and/or esophageal ulceration
  5. History of difficulty swallowing (dysphagia) or painful swallowing (odynophagia), including swallowing pills
  6. Oropharyngeal tumor
  7. History of esophageal or gastric surgery, with exception of uncomplicated surgical fundoplication procedure
  8. History of myocardial infarction or cerebrovascular accident within past 6 months
  9. Any known lesion which, in the opinion of the endoscopist, obstructs greater than 25% of the esophageal lumen
  10. Prior participation in PR-0139/EG-CL-101 (Lucid BE Screening Study)
  11. Prior EGD during which a therapeutic procedure such as, but not limited to, ablation, cryotherapy or endoscopic mucosal resection, was performed for the treatment of BE and/or EAC
  12. History of esophageal motility disorder
  13. Currently implanted Linx device
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
784 participants (actual)

Study arms

  • Experimental
    EsoCheck and EsoGuard vs. EGD with or without biopsies

    All subjects will undergo both the EsoGuard lab assay run on distal esophageal cells collected with EsoCheck (non-invasive esophageal cell sample collection) device followed by Esophagogastroduodenoscopy (EGD) with or without biopsies

    Device: EsoGuard (lab assay) · Diagnostic Test: Esophagogastroduodenoscopy

Interventions

  • DeviceEsoGuard (lab assay)

    EsoGuard assay (LDT) will be used on cells collected using the EsoCheck (510K cleared esophageal cell collection device)

    Also known as: EsoCheck (esophageal cell sample collection device)

  • Diagnostic testEsophagogastroduodenoscopy

    Planned EGD to diagnose and/or treat disorders of esophagus, stomach, and small intestine. When abnormal tissues are noted, biopsies of the tissue are taken through the scope to diagnose tissue abnormalities.

    Also known as: EGD

06

What researchers measure

Primary outcomes

  1. Primary Efficacy

    The primary efficacy endpoint is the sensitivity of EsoGuard. The primary efficacy objectives of this study are to measure the sensitivities of EsoGuard-based diagnosis in 54 cases each of non-dysplastic Barrett's Esophagus (NDBE), low grade dysplasia (LGD), high grade dysplasia (HGD), and intramucosal adenocarcinoma (IMC) in order to assess EsoGuard's ability to detect disease across the entire continuum of disease progression.

    Time frame: Per subject analysis through study completion which is up to approximately 5 weeks

Secondary outcomes

  1. Secondary Efficacy

    The secondary efficacy outcome will be the specificity of EsoGuard (which are run on samples collected using EsoCheck) for Controls. Specificity of EsoGuard will be calculated for the controls as the number of controls who test negative via EsoGuard divided by the total number of controls.

    Time frame: Per subject through study completion which is up to approximately 5 weeks

Other outcomes

  1. Safety outcome of EsoCheck Device (510k cleared, non-invasive, esophageal cell collection device) on all patients who undergo the device procedure.

    Assessed by evaluation of esophageal abrasions (as visualized during esophagogastroduodenoscopy\[EGD\]) when EsoCheck and EGD procedures are performed the same day as well as adverse events (AEs) serious adverse events (SAEs), adverse device effects (ADEs), serious adverse devices effects (SADEs), unanticipated serious adverse device effects (USADEs) and Medical Device Deficiency Incidents.

    Time frame: Per subject through study completion which is up to approximately 5 weeks

07

Study locations

35 sites
  • Lucid Investigative Site
    Aurora, Colorado 80045, United States
  • Lucid Investigative Site
    Englewood, Colorado 80113, United States
  • Lucid Investigative Site
    Washington D.C., District of Columbia 20007, United States
  • Lucid Investigative Site
    Jacksonville, Florida 32256, United States
  • Lucid Investigative Site
    Chicago, Illinois 60611, United States
  • Lucid Investigative Site
    Shreveport, Louisiana 71105, United States
  • Lucid Investigative Site
    Baltimore, Maryland 21287, United States
  • Lucid Investigative Site
    Boston, Massachusetts 02215, United States
  • Lucid Investigative Site
    Ann Arbor, Michigan 48109, United States
  • Lucid Investigative Site
    Flowood, Mississippi 39232, United States
  • Lucid Investigative Site
    St Louis, Missouri 63110, United States
  • Lucid Investigative Site
    Omaha, Nebraska 68124, United States
  • Lucid Investigative Site
    Lebanon, New Hampshire 03756, United States
  • Lucid Investigative Site
    New Hyde Park, New York 11030, United States
  • Lucid Investigative Site
    Rochester, New York 14620, United States
  • Lucid Investigative Site
    Chapel Hill, North Carolina 27599, United States
  • Lucid Investigative Site
    Portland, Oregon 97239, United States
  • Lucid Investigative Site
    Philadelphia, Pennsylvania 19104, United States
  • Lucid Investigative Site
    Philadelphia, Pennsylvania 19107, United States
  • Lucid Investigative Site
    Charleston, South Carolina 29425, United States
  • Lucid Investigative Site
    Greenville, South Carolina 29615, United States
  • Lucid Investigative Site
    Knoxville, Tennessee 37909, United States
  • Lucid Investigative Site
    Nashville, Tennessee 37212, United States
  • Lucid Investigative Site
    Austin, Texas 78712, United States
  • Lucid Investigative Site
    Dallas, Texas 75246, United States
  • Lucid Investigative Site
    Houston, Texas 77030, United States
  • Lucid Investigative Site
    Salt Lake City, Utah 84132, United States
  • Lucid Investigative Site
    Richmond, Virginia 23249, United States
  • Lucid Investigative Site
    Richmond, Virginia 23298, United States
  • Lucid Investigative Site
    Amsterdam, 1081 HZ, Netherlands
  • Lucid Investigative Site
    Eindhoven, 5623 EJ, Netherlands
  • Lucid Investigative Site
    Groningen, 9713 GZ, Netherlands
  • Lucid Investigative Site
    Nieuwegein, 3435 CM, Netherlands
  • Lucid Investigative Site
    Nijmegen, 6525 GA, Netherlands
  • Lucid Investigative Site
    Rotterdam, 3015 GD, Netherlands
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2020 (actual). Primary completion is estimated for Jun 2027, 83 months after the start.

Of 76 interventional studies with no phase under Barrett Esophagus, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 108. This study's planned 83 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 29, 2020
First posted
Mar 5, 2020
StartActual
Jun 18, 2020
Primary completionEst.
Jun 1, 2027
CompletionEst.
Jun 1, 2027
Last update
Sep 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04295811
Lead sponsor
Lucid Diagnostics, Inc.
Responsible party
Sponsor
First posted
Mar 5, 2020
Start date
Jun 18, 2020
Primary completion
Jun 1, 2027 (estimated)
Completion
Jun 1, 2027 (estimated)
Last update
Sep 21, 2026

Study contacts

Victoria Lee, MD
study chair · Lucid Diagnostics, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion